Meeting
2017 ASCO Annual Meeting
A phase 3 trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer.
Authors
Willemien Van Driel
Center for Gynecologic Oncology, Amsterdam, Netherlands
Willemien Van Driel , Karolina Sikorska , Jules Schagen van Leeuwen , Henk Schreuder , Ralph Hermans , Ignace de Hingh , Jacobus Van Der Velden , Henriëtte J.G. Arts , Massuger Leon , Arend Aalbers , Verwaal Victor J. , Koen van der Vijver , Neil K Aaronson , Gabe S. Sonke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT00426257
Citation
J Clin Oncol 35, 2017 (suppl; abstr 5519)
DOI
10.1200/JCO.2017.35.15_suppl.5519
Abstract #
5519
Poster Bd #
341
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Primary cytoreductive surgery with or without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: The OVHIPEC-2 trial in progress.
First Author: Ruby M. van Stein
Poster
2024 ASCO Annual Meeting
Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage III and IV ovarian cancer after interval cytoreductive surgery (FOCUS).
First Author: Myong Cheol Lim
Poster
2022 ASCO Annual Meeting
Cytoreductive surgery plus HIPEC for advanced epithelial ovarian cancer: Analysis from a multicentric national Indian HIPEC registry of 1,470 patients—An ISPSM Collaborative study.
First Author: S.P. Somashekhar
Poster
2014 ASCO Annual Meeting
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial.
First Author: Gottfried E. Konecny